Silexion Therapeutics Corp(SLXN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. GRAND CAYMAN, Cayman Islands, November 14, 2024 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported i ...